Leukaemia Trial, Recruiting (NCT06625372)

Leukaemia Trial, Recruiting NCT06625372 Sponsor: Shahid Beheshti University Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06625372 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child's legal guardian must be willing to give consent and complete the required paperwork
The child must be 18 years old or younger
The child must have a confirmed diagnosis of acute leukemia and be a candidate for a stem cell transplant
The child must be suitable to receive nutrition delivered through a vein (intravenous nutrition)
There must be no medical reasons preventing the child from receiving intravenous nutrition
The child must have no history of allergy to egg or soy protein
The child must not have severe organ failure or significantly reduced liver function (confirm with trial site for specific test values)

Who may not be able to join:

Children who pass away within the first 5 days after the intervention begins
Families or guardians who are unwilling to continue participating during the study
Children who experience side effects during the study
Children who develop serious complications such as a severe infection in the bloodstream, dangerously low blood pressure, shock, blood clots, a heart attack, or liver problems during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zahra Vahdat Shariatpanahi, Professor, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences

Phone: 0098-021-22357484

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06625372

Sponsor: Shahid Beheshti University

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: 0098-021-22357484

More information: https://clinicaltrials.gov/study/NCT06625372

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child's legal guardian must be willing to give consent and complete the required paperwork
The child must be 18 years old or younger
The child must have a confirmed diagnosis of acute leukemia and be a candidate for a stem cell transplant
The child must be suitable to receive nutrition delivered through a vein (intravenous nutrition)
There must be no medical reasons preventing the child from receiving intravenous nutrition
The child must have no history of allergy to egg or soy protein
The child must not have severe organ failure or significantly reduced liver function (confirm with trial site for specific test values)

Who may not be able to join:

Children who pass away within the first 5 days after the intervention begins
Families or guardians who are unwilling to continue participating during the study
Children who experience side effects during the study
Children who develop serious complications such as a severe infection in the bloodstream, dangerously low blood pressure, shock, blood clots, a heart attack, or liver problems during the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Shahid Beheshti University

Registry

ClinicalTrials.gov

Start date

12 October 2024

Est. completion

1 August 2025

Where this trial is recruiting

Iran

Primary endpoints

Engraftment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov